These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34547714)

  • 1. Design, synthesis, and biological evaluation of novel Bcr-Abl
    Pan X; Liu N; Zhang Q; Wang K; Li Y; Shan Y; Li Z; Zhang J
    Bioorg Med Chem; 2021 Oct; 48():116398. PubMed ID: 34547714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel Bcr-Abl
    Pan X; Liang L; Sun Y; Si R; Zhang Q; Wang J; Fu J; Zhang J; Zhang J
    Eur J Med Chem; 2019 Sep; 178():232-242. PubMed ID: 31185413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expanding the structural diversity of Bcr-Abl inhibitors: Dibenzoylpiperazin incorporated with 1H-indazol-3-amine.
    Shan Y; Dong J; Pan X; Zhang L; Zhang J; Dong Y; Wang M
    Eur J Med Chem; 2015 Nov; 104():139-47. PubMed ID: 26451772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity.
    El-Damasy AK; Jin H; Seo SH; Bang EK; Keum G
    Eur J Med Chem; 2020 Dec; 207():112710. PubMed ID: 32961435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure optimization, synthesis and bioactivity evaluation of novel BCR-ABL tyrosine kinase inhibitor targeting T315I mutation.
    Wang S; Chen J; Hou R; Xiong Y; Shi H; Chen Z; Li J; Wang X
    Chem Biol Interact; 2024 Nov; 403():111248. PubMed ID: 39332790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of a Candidate Containing an (
    Zhang D; Li P; Gao Y; Song Y; Zhu Y; Su H; Yang B; Li L; Li G; Gong N; Lu Y; Shao H; Yu C; Huang H
    J Med Chem; 2021 Jun; 64(11):7434-7452. PubMed ID: 34011155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH
    Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of Alkyne-Containing Pyrazolopyrimidines To Overcome Drug Resistance of Bcr-Abl Kinase.
    Liu X; Kung A; Malinoski B; Prakash GK; Zhang C
    J Med Chem; 2015 Dec; 58(23):9228-37. PubMed ID: 26562217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and biological evaluation of trizole-based heteroaromatic derivatives as Bcr-Abl kinase inhibitors.
    Pan X; Liu N; Liu Y; Zhang Q; Wang K; Liu X; Zhang J
    Eur J Med Chem; 2022 Aug; 238():114425. PubMed ID: 35561654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MPT0B002, a novel microtubule inhibitor, downregulates T315I mutant Bcr-Abl and induces apoptosis of imatinib-resistant chronic myeloid leukemia cells.
    Yeh YY; Liou JP; Lee YL; Lin JY; Huang HM
    Invest New Drugs; 2017 Aug; 35(4):427-435. PubMed ID: 28349229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia.
    Liu X; Wang B; Chen C; Jiang Z; Hu C; Wu H; Zhang Y; Liu X; Wang W; Wang J; Hu Z; Wang A; Huang T; Liu Q; Wang W; Wang L; Wang W; Ren T; Li L; Xia R; Ge J; Liu Q; Liu J
    Eur J Med Chem; 2018 Dec; 160():61-81. PubMed ID: 30317026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and identification of GZD856 as an orally bioavailable Bcr-Abl
    Lu X; Zhang Z; Ren X; Wang D; Ding K
    J Enzyme Inhib Med Chem; 2017 Dec; 32(1):331-336. PubMed ID: 28260399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
    Jin B; Wang C; Shen Y; Pan J
    Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
    Xu F; Shi X; Li S; Cui J; Lu Z; Jin Y; Lin Y; Pang J; Pan J
    Bioorg Med Chem; 2010 Mar; 18(5):1806-15. PubMed ID: 20149665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
    Li Y; Shen M; Zhang Z; Luo J; Pan X; Lu X; Long H; Wen D; Zhang F; Leng F; Li Y; Tu Z; Ren X; Ding K
    J Med Chem; 2012 Nov; 55(22):10033-46. PubMed ID: 23088644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.
    Huang WS; Metcalf CA; Sundaramoorthi R; Wang Y; Zou D; Thomas RM; Zhu X; Cai L; Wen D; Liu S; Romero J; Qi J; Chen I; Banda G; Lentini SP; Das S; Xu Q; Keats J; Wang F; Wardwell S; Ning Y; Snodgrass JT; Broudy MI; Russian K; Zhou T; Commodore L; Narasimhan NI; Mohemmad QK; Iuliucci J; Rivera VM; Dalgarno DC; Sawyer TK; Clackson T; Shakespeare WC
    J Med Chem; 2010 Jun; 53(12):4701-19. PubMed ID: 20513156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of novel aromatic-heterocyclic biphenyls as potent anti-leukemia agents.
    Dong J; Pan X; Wang J; Su P; Zhang L; Wei F; Zhang J
    Eur J Med Chem; 2015 Aug; 101():780-9. PubMed ID: 26231079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.